Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety of the investigational study drug, BGB324
when administered in combination with docetaxel, and to establish the maximum tolerated dose.
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
BerGenBio AS BerGenBio ASA Texas Tech University Health Sciences Center